

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

Listing of Claims

1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain approximately ~~42-17~~ to 40 amino acids in length that binds to G-CSFR and contains a sequence of amino acids selected from the group consisting of GGGLLDICELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211); LLDICEELKLQEAARRCN (SEQ ID NO: 212); KLLDICELKLQEAARRCN (SEQ ID NO: 213); and LLDICELKLQECARRAN (SEQ ID NO: 343).

~~of formula (V) (V) $CX^{IV}_1X^{IV}_2X^{IV}_3X^{IV}_4X^{IV}_5X^{IV}_6X^{IV}_7X^{IV}_8X^{IV}_9X^{IV}_{10}C$ (SEQ ID NO: 5) wherein each amino acid is indicated by standard one letter abbreviation, and wherein X^{IV}_1 is E, G, P, N, R, T, W, S, L, H, A, Q or Y; X^{IV}_2 is S, T, E, A, D, G, W, P, L, N, V, Y, R or M; X^{IV}_3 is R, Y, V, Q, E, T, L, P, S, K, M, A or W; X^{IV}_4 is L, M, G, F, W, R, S, V, P, A, D, C or T; X^{IV}_5 is V, T, A, R, S, L, W, C, I, E, P, H, F, D or Q; X^{IV}_6 is E, Y, G, T, Q, M, S, N, A or P; X^{IV}_7 is C, V, D, G, L, W, E, V, I, S, M or A; X^{IV}_8 is S, Y, A, W, P, V, L, Q, G, K, F, I, E or D; X^{IV}_9 is R, W, M, D, H, V, G, A, Q, L, S, E or Y; X^{IV}_{10} is M, L, I, S, V, P, W, F, T, Y, R, or Q; and wherein said compound does not comprise sequence LLDICELKLQECARRCN (SEQ ID NO: 208).~~

163. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLQECARRCN (SEQ ID NO: 209).

~~X^{IV}_1 is E, X^{IV}_2 is S or A, X^{IV}_3 is R, X^{IV}_4 is L, X^{IV}_5 is V or S, X^{IV}_6 is E, X^{IV}_7 is C, X^{IV}_8 is S, X^{IV}_9 is R, and X^{IV}_{10} is L.~~

164. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210).

~~the sequence of amino acids is selected from the group consisting of:~~

~~GGGLLDICELKLQECARRCN (SEQ ID NO: 209);~~


~~GRTGGLLDICEELKLQECARRCN (SEQ ID NO: 210);~~

~~LGIEGRTGGGLLDICEELKLQECARRC-N (SEQ ID NO: 211);~~

~~LLDICEELKLQEAARRCN (SEQ ID NO: 212); and~~

~~KLLDICEELKLQEAARRCN (SEQ ID NO: 213).~~

165. (Currently amended) The compound of claim 162, comprising a dimer having the structure of formula (VIII)



wherein R^1 and R^2 are independently selected from the sequences of amino acids of claim 1; ~~formula (V)~~; βA is a β -alanine residue; $n1$, $n2$, $n3$, $n4$, x and y are independently zero or one with the proviso that the sum of x and y is either one or two; and Lk is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two-NH-linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Previously presented) The compound of claims 162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

170. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of any claim 162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.

175. (New) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211).

176. (New) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN (SEQ ID NO: 212).

177. (New) The compound of claim 162, wherein said sequence of amino acids is KLLDICELKLQEAARRCN (SEQ ID NO: 213).

178. (New) The compound of claim 162, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343).